Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 779 results for "Tecfidera"

Biogen Idec announces encouraging data from Phase III multiple...

Biogen Idec, a biotechnology company, has announced that five-year data from the ENDORSE Phase III extension study show TECFIDERA provides sustained efficacy in a broad range of people living with relapsing-remitting multiple sclerosis, or RRMS., 4 days ago

7 images for Tecfidera

Pharma Letter, 1 week ago
Drug Discovery and Development, 1 week ago
Nasdaq, 1 week ago
FDA News, 2 weeks ago, 1 month ago
Pharma Letter, 2 months ago
ABC News 4 Charleston, 2 months ago
Pharma Letter

Dimethyl fumarate (Tecfidera) follow on study

11 September 2014 Author: Results from a five year follow on study show dimethyl fumarate remained effective over that period and there was no increased risk of side effects. People who started treatment when newly diagnosed showed most ...
 Multiple Sclerosis Trust1 week ago Strong and sustained efficacy reported for Tecfidera over five years12-09-2014  Pharma Letter1 week ago Biogen Idec's Phase 3 Study With Tecfidera Show Positive Data Over 5 Years  RTTNews.com1 week ago Biogen Idec, Inc. (Massachusetts) Release: New Data From ENDORSE Show Positive Results Continued Over Five Years With TECFIDERA® (Dimethyl Fumarate) In A Wide Range Of Multiple Sclerosis Patients  BioSpace1 week ago
FDA News

NICE Recommends MS Drug Tecfidera

Biogen Idec said it will launch its multiple sclerosis drug Tecfidera within three months in England and Wales following a final coverage recommendation from the UK healthcare pricing watchdog. The National Institute for Health and Care ...
 FDA News2 weeks ago IQWiG finds no added benefit for Biogen Idec's Tecfidera08-08-2014  Pharma Letter1 month ago UPDATED: Germany gives an initial 'no additional benefit' on Biogen Idec's Tecfidera  FiercePharma1 month ago UPDATED Germany gives an initial no additional benefit on Biogen Idecs Tecfidera  Big News Network1 month ago

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 1, Authorised

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency1 month ago

Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues

It was a busy week in the biotech sector with quite a few major companies reporting second quarter earnings. Outperformers included companies like Biogen ( BIIB ) and Gilead ( GILD ) both reported impressive numbers that sailed past expectations. ...
 Yahoo! Finance1 month ago Biotech Stock Roundup: Amgen Plans Job Cuts, Regeneron's Eylea Continues to Impress - Analyst Blog  Zacks.com1 month ago Alexion, 3 Other Top Biotechs Reporting Earnings  Investor's Business Daily2 months ago

Biogen revenue trounces forecast as MS drug sales surge

July 23 (Reuters) - Biogen Idec Inc reported sharply higher-than-expected quarterly revenue on surging sales of its new Tecfidera oral treatment for multiple sclerosis, and the company raised its full-year profit forecast. The company on ...
 CNBC2 months ago Storming Tecfidera sales drive 46 profit rise at Biogen  Big News Network1 month ago UPDATE 4-Biogen revenue trounces forecast as MS drug sales surge  Reuters1 month ago CORRECTED-UPDATE 3-Biogen revenue trounces forecast as MS drug sales surge  Reuters1 month ago

Biogen Trounces Q2 Estimates As Tecfidera Outperforms

Big-cap biotech Biogen Idec (NASDAQ: BIIB ) soundly beat analysts' Q2 expectations and substantially raised its guidance early Wednesday, sending shares up more than 11% in midday trading in the stock market today to near 338, a four-month high. ...
 Investor's Business Daily2 months ago Video: Biogen Trounces Q2 Estimates On Tecfidera  Investor's Business Daily1 month ago

Biogen's Q2 Earnings Surpass Expectations, Tecfidera Shines

Biogen Idec (BIIB) reported second quarter 2014 earnings per share of $3.48 (including the impact of stock-based compensation expense), way above the Zacks Consensus Estimate of $2.80 and the year-ago earnings of $2.29 per share. While oral ...
 Yahoo! Finance2 months ago Biogen Idec Stock Spikes Following Second Quarter Earnings Beat  TheStreet.com2 months ago

Biogen Beats Quarterly Analyst Estimates with New Drug Sales

Biogen Idec Inc. (BIIB) , maker of multiple sclerosis drugs Avonex, Tysabri and Tecfidera, beat analyst estimates with better than expected sales of Tecfidera and new hemophilia drug Alprolix. The company raised its 2014 forecast. Net income for ...
 Bloomberg2 months ago Pop some corks, Tecfidera sales folks: Your $700M for Q2 trounced estimates  FiercePharma2 months ago

Could This 1 Lawsuit Destroy Biogen Idec Stock?

Source: Biogen IDEC. Biogen 's ( NASDAQ: BIIB ) Tecfidera launched a year ago, and it has already become a blockbuster likely to notch more than $2 billion in sales this year. Much of Tecfidera's success is coming at the expense of recently ...
 Motley Fool2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less